About STnRadio
A focused company built on a differentiated antibody and a modern platform.
Our mission
Our mission is to deliver precision radiation therapy to patients with solid tumors that conventional treatment cannot reach. We build on a highly selective antibody and modern theranostic chemistry to bring meaningful benefit to patients with STn-expressing cancers.
How STnRadio was founded
STnRadio was founded in 2026 to translate a highly selective anti-STn antibody into a clinical radio-theranostic product. The company brings together expertise in biotechnology leadership, radioligand chemistry, and translational oncology to bridge the gap from scientific discovery to first patient.
Partners & collaborators
- Partners will be announced as collaborations are formalised — CDMOs, isotope suppliers, clinical sites.
Contact us
Whether you are an investor, a potential partner, a clinician, a scientist, or a candidate interested in joining the team, we'd like to hear from you.